- William (Bill) J. Ciprick has been appointed as the Chief Executive Officer, effective September 7, 2021
- Mr. Ciprick brings over 30 years of global experience across a wide array of industries
- Mr. Ciprick holds a Bachelor of Arts degree in Economics from the University of British Columbia
- Optimi has granted 73,077 common shares and issued 1,000,000 incentive stock options to Mr. Ciprick
- Optimi Health Corp. is developing a Canadian functional mushroom brand that focuses on the health and wellness food markets
- Optimi Health Corp. (OPTI) opened trading at C$0.65 per share
Optimi Health (OPTI) is pleased to announce that William (Bill) J. Ciprick has been appointed as the Chief Executive Officer, effective September 7, 2021.
Mr. Ciprick brings over 30 years of global experience across a wide array of industries ranging from Fortune 500 corporations to small and medium-sized Canadian businesses. Throughout his career, he has developed a broad set of skills with a focus on growth strategies, sales, marketing, organizational development, mergers, acquisitions, and turnarounds.
He recently served as Senior Vice President at BDC Advisory Services. In this role, he was responsible for leading BDC’s High-Impact Firm team, as well as the successful execution of related programs.
Previously, Mr. Ciprick was President and Executive Consultant with ATG Consulting, focusing on conducting organizational assessments and redesigns, and on developing and supporting the development and implementation of strategic plans.
Prior to ATG, Mr. Ciprick was Vice President of Strategy and Business Development for SMART Technologies, where he developed and deployed the first strategic planning process and delivered the largest acquisition in the company’s history.
He also spent more than 16 years at Procter & Gamble, holding management positions including Senior Vice President, Sales for the P&G North America Beauty division. Mr. Ciprick holds a Bachelor of Arts degree in Economics from the University of British Columbia.
In agreeing to join Optimi as its Chief Executive Officer, Bill Ciprick commented,
“I am delighted and excited by the Optimi opportunity. The company is rapidly moving beyond their initial start-up and build-out into commercialization of functional mushroom products concurrent with their advanced research and studies aimed at the increasingly important mental health & wellness field. The commitment the entire Optimi team brings to achieving the highest industry standards for the scientific investigation and development of an all-natural mushroom product platform is in my opinion second-to-none, and represents an attractive business proposition. I have found the business to be structurally sound and ready to grow – which is a testament to their initial start-up approach. I look forward to helping build Optimi into a sector-leading commercial enterprise.”
Outgoing CEO Mike Stier advised,
“The work we undertook since inception, and ultimately with our public listing, has provided the initial market visibility and financing to enable healthy progress and created a detailed roadmap for future growth. Now is the time for a steady hand focussed on commercialization and product development. Bill has the leadership experience and background we believe will guide the Company into the next phase of development. With leaders like Bill participating in the sector, I look forward to a bright future for Optimi Health and the industry as a whole.”
Mr. Ciprick is replacing Mike Stier. Optimi is pleased to announce that he will remain as a director of the company.
In connection with his appointment, Optimi has granted 73,077 common shares and issued 1,000,000 incentive stock options to Mr. Ciprick. Each stock option entitles Mr. Ciprick to acquire one common share at a price of $1.50 until August 31, 2026.
Optimi Health Corp. is developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness food markets.
The company also intends to cultivate, extract, process and distribute high-quality strains of fungi products at its GMP-certified facility located in Princeton, British Columbia.
Optimi Health Corp. (OPTI) opened trading at C$0.65 per share.
